≪研究成果≫
【2003－2004】
１．Koga, M., Shichijo, S., Yamada, A., Ashihara, J., Sawamizu, H., Kosukawa, J., and Itoh K., Identification of ribosomal proteins S2 and L10a as tumor antigens recognized by HLA-A26-restricted CTL. Tissue Antigens, 61(2):136-145, 2003.
２．Azuma, K., Shichijo, S., Maeda, Y., Nonaka, Y., Fujii, T., Kenta, K., and Itoh, K. Mutated p53 gene encodes a non-mutated epitope recognized by HLA-B4601-restrited and tumor-reactive CTLs at tumor site. Cancer Res 63(4) 854-858, 2003.
３．Yamada, A., Kawano, K., Koga, M., Takamori. S., Nakagawa, M., and Itoh, K. Gene and peptide analyses of newly defined lung cancer rejection antigens recognized by HLA-A2402-restricted tumor-specific cytotoxic Tlymphocytes. Cancer Res, 63(11):2829-2835, 2003.
４．Noguchi, M., Kobayashi, K., Suetsugu, N., Tomiyasu, K., Suekane, S.,
Yamada, A., Itoh, K. and Noda, S. Induction Of Cellular And Humoral Immune
Responses To Tumor Cells And Peptides In HLA-A24 Positive Hormone-Refractory
Prostate
Cancer Patients By Peptide Vaccination. Prostate, 57(1): 80-92,
2003.
５．Harada, M., Kobayashi, K., Matsueda, S., Nakagawa, M., Noguchi, M., and Itoh, K. Prostate-specific antigen-derived epitopes capable of inducing cellular and humoral responses in HLA-A24+ prostate cancer patients. Prostate, 57(2):152-159, 2003.
６．Kawamoto, N., Yamada, A., Ohkouchi, S., Maeda, T., Tanaka, S., Hashimoto, T., Saijo, Y., Saijo, S., Nukiwa, T., Shichijo, S., Aizawa, H., Itoh, K. IgG reactive to CTL-directed epitopes of self-antigens is enter lacking or unbalanced in atopic dermatitis patients. Tissue Antigen, 61(5):352-361, 2003.
７．Tanaka, S., Harada, M., Mine, T., Noguchi, M., Gohara, R., Azuma, K., Tamura, M., Yamada, A., Morinaga, A., Nishikori, M., Katagiri, K., Itoh, K., Yamana, H., and Hashimoto, T. Peptide vaccination for patients with melanoma and other types of cancer based on pre-existing peptide-specific cytotoxic T-lymphocyte precursors in the periphery. J Immunother. 26(4):357-366, 2003.
８．Mine,T., Gouhara, R., Hida, N., Imai,N., Azuma, K., Rikimaru, T., Katagiri, K., Nishikori, M., Sukehiro, A., Nakagawa, M., Yamada, A., Aizawa, H., Shirouzu, K., Itoh, K., and Yamana, H. Immunological evaluation of CTL precursor-oriented vaccines for advanced lung cancer patients. Cancer Sci. 94(6):548-556. 2003.
９．Kobayashi, K., Noguchi, M., Itoh, K., and Harada, M. Identification of a prostate-specific membrane antigen-derived peptide capable of eliciting both cellular and humoral immune responses in HLA-A24+ prostate cancer patients. Cancer Sci. 94(7):622-627, 2003.
10．Shichijo, S., Azuma, K., Komatsu, N., Kawamoto, N., Takedatsu, H., Shomura, H., Sawamizu, H., Maeda, Y., Ito, M., and Itoh, K. Identification of two novel tumor-associated antigens recognized by HLA-B46-restricted cytotoxic T lymphocytes. Int. J. Mol. Med., 12(6):895-902, 2003.
11．Azuma, K., Shichijo, S., Takedatsu, H., Komatsu, N., Sawamizu, H., and Itoh, K. Heat shock cognate protein 70 encodes antigenic epitopes recognised by HLA-B4601-restricted cytotoxic T lymphocytes from cancer patients. Br J Cancer, 89(6):1079-1085, 2003.
12．Ohkouchi, S., Kawamoto, N., Koga, M., Sakanashi, F., Shichijo, S., Saijo, Y., Nukiwa, T., Itoh, K., and Yamada, A. Identification of a CTL-directed epitope encoded by an intron of the putative tumor suppressor gene Testin of the common fragile site 7G region: a peptide vaccine candidate for HLA-B52+ and HLA-62+ cancer patients. Eur J Immunol., 33(11):2964-2973, 2003.
13．Sato, Y., Shomura, H., Maeda, Y., Mine, T., Une, Y., Akasaka, Y., Kondo, M., Takahashi, S., Shinohara, T., Katagiri, K., Sato, S., Okada, S., Matsui, K., Yamada, A., Yamana, H., Itoh, K., and Todo, S. Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide. Cancer Sci. 94(9):802-808, 2003.
14．Harada M, Noguchi M, Itoh K. Target molecules in specific immunotherapy against prostate cancer. Int J Clin Oncol., 8(4):193-199.（review）, 2003.
15．Matsueda, S., Kobayashi, K., Nonaka, Y., Noguchi, M., Itoh, K., and Harada, M. Identification of new prostate stem cell antigen-derived peptides immunogenic in HLA-A2+ patients with hormone-refractory prostate cancer. Cancer Immunol Immunother., 2003 Nov 21.
16．Kumamaru, W., Nakamura, S., Kadena, T., Yamada, A., Kawamura, E., Sasaki, Sasaki, M., Ohyama, Y., Toyoshima, T., Hayashida, J, Itoh, K., and Shirasuna, K. T cell receptor Vβ gene usage by T cells reactive with the tumor-rejection antigen SART-1 in oral squamous cell carcinoma., Int J Cancer., 108(5):686-695, 2004.
17．Harada, M., Gohara, R., Oda, T., Iwamoto, Y., and Itoh, K. In vivo evidence that peptide vaccination can induce HLA-DR-restricted CD4+ T cells reactive to a class I tumor peptide. J Immunol., 172:2659-2667, 2004.
18．Tsuda, N., Mochizuki, K., Harada, M., Sukehiro, A., Kawano, K., Yamada, A., Ushijima, K., Sugiyama, T., Nishida, T., Yamana, H., Itoh, K., and Kamura, T. Vaccination with predesignated or evidence-based peptides for patients with recurrent gynecologic cancers. J Immunother., 27(1):60-72, 2004.
19．Noguchi, M., Itoh, K., Suekane, S., Yao, A., Suetsugu, N., Katagiri, K., Yamada, A., Yamana, H., and Noda, S. Phase I trial of patient-oriented vaccination in HLA-A2-positive patients with metastatic hormone-refractory prostate cancer. Cancer Sci., 95(1):77-84, 2004.
20．Mine, T., Sato, Y., Noguchi, M., Sasatomi, T., Gouhara, R., Tsuda, N., Tanaka, S., Shomura, H., Katagiri, K., Rikimaru, T., Shichijo, S., Kamura, T., Hashimoto, T., Shirouzu, K., Yamada, A., Todo, S., Itoh, K., and Yamana, H. Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing peptide-specific cellular responses. Clin Cancer Res, 10:929-937, 2004.
21．Ishihara, Y., Harada, M., Azuma, K., Tamura, M., Shomura, H., Fujii, T., Itoh, K., and Shichijo, S. HER2/neu-derived peptides recognized by both cellular and humoral immune systems in HLA-A2+ cancer patients. Int. J. Oncolgy, 24: 967-975, 2004.
22．Shomura, H., Shichijo, S., Matsueda, S., Kawakami, T., Sato, Y., Todo, S., and Itoh, K. Identification of epidermal growth factor receptor-derived peptides immunogenic for HLA-A2+ cancer patients. Br. J. Cancer, Apr 19;90(8):1563-71, 2004.
23．Takedatsu, H., Shichijo, S., Azuma, K., Takedatsu, H., Sata, M., and Itoh, K. Detection of a set of peptide vaccine candidates for use in HLA-A31+ epithelial cancer patients. Int. J. Oncology, 24,337-347, 2004.
24．Ogata, R., Matsueda, S., Yao, A., Noguchi, M., and Itoh, K. Identification of polycomb group protein enhancer of zeste homolog 2(EZH2)-derived peptides immunogenic in HLA-A24+ prostate cancer patients. Prostate, in press, 2004.
25．Sato, Y., Maeda, Y., Shomura, H., Sasatomi, T., Takahashi, M., Une, Y., Kondo, M., Shinohara, T., Hida, N., Katagiri, K., Sato, M., Yamada, A., Yamana, H., Harada, M., Itoh, K., and Todo, S. A phase I trial of cytotoxic T lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients. Br. J. Cancer, Apr 5;90(7):1334-42., 2004.
26．Matsueda, S., Yao, A., Ishihara, Y., Ogata, R., Noguchi, M., Itoh, K., and Harada, M. A prostate stem cell antigen-derived peptide immunogenic in HLA-A24+ prostate cancer patients. Prostate, in press, 2004.
27．Noguchi, M., Itoh, K., Suekane, S., Furuta, M., Suetsugu, N., Katagiri, K., Yamada, A., Yamana, H., and Noda, S. Immunological monitoring during combination of patient-oriented peptide vaccination and low-dose estramustine phosphate in patients with metastatic hormone refractory prostate cancer. Prostate, in press, 2004.
28．Takao, Y., Yamada, A., Yutani, S., Sata, M., and Itoh, K. Antibody reactive to a hepatitis C virus (HCV)-derived peptide capable of including HLA-A2 restricted cytotoxic T lymphocytes is detectable in the majority of HCV-infected individuals without HLA-A2 restriction. Microbiology and Immunology, in press, 2004.
29．Yao, A., Harada, M., Matsueda, S., Ishihara, Y., Shomura, H., Takao, Y., Noguchi, M., Matsuoka, K., Hara, I, Kamidono, S., Itoh, K. New epitope peptides derived from parathyroid hormone-related protein which have the capacity to induce prostate cancer-reactive cytotoxic T lymphocytes in HLA-A2+ prostate cancer patients. Prostate, in press, 2004.
30．Mochizuki, K., Sato, Y., Tsuda, N., Shomura, H., Sakamoto, M., Matsuura, K,m Ushijima, K., Maeda, Y., Katagiri, K., Yamada, A., Todo, S., Kamura, T., and Itoh, K. Immunological evaluation of pre-designated vaccination of the peptides frequently vaccinated to cancer patients in individualized peptide vaccination regimen. Int. J. Oncol. in press, 2004.
31．Takedatsu H., Shichijo S., Katagiri K., Sawamizu H., Sata M., Itoh K.: Identification of peptide vaccine candidates sharing among HLA-A3+, -A11+, -A31+ and -A33+ cancer patients. Clin. Cancer Res. 10: 1112-1120, 2004.
32．Sasada T., Takedatsu H., Azuma K., Koga M., Maeda Y.,Shichijo S., Shoumura H., Hirai T., Takabayashi A., Itoh K.: IEX-1, a stress inducible anti-apoptotic gene, encodes CTL epitopes capable of inducing HLA-A33-restricted and tumor-reactive CTLs in gastric cancer patients. Cancer Res. Apr 15;64(8):2882-8, 2004.
33．Azuma K., Shichijo, S., Shomura H., Matsueda S., Fujii T., Itoh K.: Identification of HER2/neu-derived peptides capable of inducing both cellular and humoral immune responses in HLA-A24 positive breast cancer patients. Breast Cancer Res. Treat. in press, 2004.
34．Koga M., Komatsu N., Kawamoto N., Shichijo S., Itoh K., Yamada A.: Analysis of cellular localization of SART3 tumor antigen by a newly established monoclonal antibody: Heterotopic expression of SART3 on the surface of B-lineage leukemic cells. Oncol. Rep, 11: 785-789, 2004.
35．Fukuda K., Takao Y., Miyazaki Y., Itoh K., Yamada A.: New type of natural antibodies reactive to class I-MHC binding peptides. Immunobilology. in press,2004.
36．Noguchi M., Noda S., Yoshida M., Ueda S., Shiraishi T., Itoh K., and The Kurume ?Kumamoto Estracyt Study Group: Chemohormonal therapy as primary treatment for metastatic prostate cancer: A randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist. Int. J. Urology, 11,103-109, 2004.
37．Bednarczuk T., Hiromatsu Y., Seki N., Ploski R., Fukutani T.,
Kurylowicz A., Jazdzewski K., Chojnowski K., Itoh K., Nauman J. Association of
tumor necrosis factor (TNF) and HLA-DRB1 alleles with
38．Komatsu N., Shichijo S., Nakagawa M., and Itoh K. New multiplexed flow cytometric assay to measure anti-peptide antibody: A novel tool for monitoring immune responses to peptides used for immunization. Scandinavian Journal of Clinical & Laboratory Investigation. Accept,2004.
39．Shomura H, Shichijo S, Komatsu N, Matsueda S, Mine T, Rikimaru T, Sato Y, Todo S, and Itoh K. Identification of epidermal growth factor receptor-derived peptides recognized by both cellular and humoral immunities in HLA-A24＋ non-small cell lung cancer patients. Eur. J Can. in press, 2004.
40．Ikewaki Ｎ, Yamada A, and Inoko H. Depolymerization of actin filament by cytochalasin E induces interleukin-8 production and up-regulates CD54 in the Hela epithelial cell line. Microbiol. Immunol., 47:775-783, 2003.
41．Fukuda K, Takao Y, Miyazaki Y, Itoh K, and Yamada A.Natural antibodies reactive to self peptides which had been identified as cytotoxic T-lymphocyte (CTL)-directed tumor antigens.Immunobiology, in press,2004.
42．Saisho Hattori T, Komatsu N, Shichijo S, Itoh K.Protein-bound polysaccharide K induced apoptosis of the human Burkitt lymphoma cell line, Namalwa. Biomedicine & Pharmacotherapy, in press, 2004
43．Fujii T, Nakagawa S, Hanzawa M, Sueyoshi S, Fujita H, Shirouzu K, Yamana H: Immunohistochemical study of cell cycle-related factors, oncogene expression, and cell proliferation in adenocarcinoma developed in Barrett’s esophagus. Oncol Reports 10(2):427-431, 2003.
44．Fujita H, Sueyoshi S, Tanaka T, Fujii T, Toh U, Mine T, Sasahara H, Sudo T, Matono S, Yamana H, Shirouzu K.: Optimal lymphadenectomy for squamous cell carcinoma in the thoracic esophagus: Comparing the short- and long-term outcome among the four types of lymphadenectomy. World J Surg 27(5):571-579, 2003.
45．Ogata Y, Fujita H, Yamana H, Sueyoshi S, Shirouzu K.: Expression of vascular endothelial growth factor as a prognostic factor in node-positive squamous cell carcinoma in the thoracic esophagus: Long-term follow-up study. World J Surg 27(5): 584-589, 2003.
46．Heroor A, Fujita H, Sueyoshi S, Tanaka T, Toh U, Mine T, Sasahara H, Sudo T, Matono S, Yamana H, Shirouzu K.: Adjuvant chemotherapy after radical resection of squamous cell carcinoma in the thoracic esophagus: who benefits? A retrospective study. Dig Surg 20(3): 229-235, 2003.
47．Sudo T, Sueyoshi S, Fujita H, Yamana H, Shirouzu K.: Esophageal perforation caused by a press though pack. Dis Esophagus 16(2): 169-172, 2003.
48．Matono S, Tanaka T, Sueyoshi S, Yamana H, Fujita H, Shirouzu K: Bystander effect in suicide gene therapy is directly proportional to the degree of gap junctional intracellular communication in esophageal cancer. Int J Oncol 23(5): 1309-1315, 2003.
49．Nakagawa S, Fujii T, Yokoyama G, Kazanietz MG, Yamana H, Shirouzu K: Cell growth inhibition by all-trans retinoic acid in SKBR-3 breast cancer cells: involvement of protein kinase Cα and extracellular signal-regulated kinase motogen-activated protein kinase. Mol Carcinog 38(3): 106-116, 2003.
50．Ando N, Iizuka T, Ide H, Ishida K, Shinoda M, Nishimaki T, Takiyama W, Watanabe H, Isono K, Aoyama N, Makuuchi H, Tanaka O, Yamana H, Ikeuchi S, Kabuto T, Nagai K, Shimada Y, Kinjo Y, Fukuda H : Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: A Japan Clinical Oncology Group Study-JCOG9204. J Clin Oncol 21(24): 4592-4596, 2003.
51．Kubota M, Sueyoshi S, Fujita H, Fujii T, Yamana H, Shirouzu K: Spontaneous regression in small cell esophageal carcinoma. Jpn J Thoracic Cardiovasc Surg 51(12): 660-664, 2003.
52．Umemoto N, Demitsu T, Toda S, Noguchi T, Suzuki SI, Kakurai M, Yamada T, Suzuki M, Nakagawa H, Komai A, Hashimoto T. Links No abstract A case of anti-p200 pemphigoid clinically mimicking inflammatory epidermolysis bullosa acquisita. Br J Dermatol. 148(5):1058-1060,2003.
53．Kozlowska A, Hashimoto T, Jarzabek-Chorzelska M, Amagai M, Nagata Y, Strasz Z, Jablonska S: Pemphigus herpetiformis with IgA and IgG antibodies to desmoglein 1 and IgG antibodies to desmocollin 3. J Am Acad Dermatol 48:117-122,2003.
54．Hamada T, Wessagowit V, South AP, Ashton GH, Chan I, Oyama N, Siriwattana A, Jewhasuchin P, LenaneS, Krafchik B, Kulthanan K, Shimizu H, Kaya TI, Erdal ME, Paradisi M, Paller AS, Hashimoto T, McGrath JA: Extracellular Matrix protein 1 gene (ECM1) mutation in lipoid proteinosis and genotype-phenotype correlation. J Invest Dermatol. 120(3):345-350,2003.
55．Hashimoto T: Recent advances in the study of pathophysiology in pemphigus (Review article). Arch Dermatol Res 295:S2-S11,2003.
56．Lee JB, Fumimori T, Kurose K, Mori O, Hashimoto T: A case of bullous pemphigoid successfully treated by plasmapheresis: Assessment of the change in titers of circulating antibodies by immunoblotting and enzyme-linked immunosorbent assay. J Dermatol 30(4):326-31,2003.
57．Niimi Y, Kawana S, Hashimoto T, Kusunoki T: Paraneoplastic pemphigus associated with uterine carcinoma, J Am Acad Dermatol 48(5 Suppl):S69-72,2003.
58．Hisamatsu Y, Abreu Velez AM, Amagai M, Ogawa MM, Kanzaki T, Hashimoto T: Comparative study of autoantigen profile between Colombian and Brazilian endemic pemphigus foliaceus by various biochemical and molecular biological techniques. J Dermatol Sci 32(1):33-41,2004.
59．Lee JB, Liu Y, Hashimoto T: Cicatricial pemphigoid sera specifically react with the most C-terminal portion of BP180. J Dermatol Sci, 32(1):59-64,2003.
60．McMillan JR, Matsumura T, Hashimoto T, Schumann H, Bruckner-Tuderman L, Shimizu H: Immunomapping of EBA sera to multiple epitopes on collagen VII: further evidence that anchoring fibrils originate and terminate in the lamina densa. Exp Dermatol. 12(3):261-7,2003.
61．Umemoto N, Demitsu T, Toda S, Ohsawa M, Noguchi T, Kakurai M, Yamada T, Suzuki M, Nakagawa H, Komai A, Hashimoto T: A Case of Nonscarring Subepidermal Blistering Disease Associated with Autoantibodies Reactive with Both Type VII Collagen and Laminin 5. Dermatology 207(1):61-64,2003.
62．Liu Y, Shimizu H, Hashimoto T: Immunofluorescence studies using skin section of recessive dystrophic epidermolysis bullosa patients indicated that the antigen of anti-p200 pemphigoid is not a fragment of type VII collagen, J Dermatol Sci 32(2):125-129,2003.
63．Tsukada Y, Kawase MK, Murashima A, Kitahora T, Hashimoto T, Komai A: Bullous pemphigoid associated with dermatomyositis successfully controlled with minocycline. Clin Exp Dermatol. 28(5):563-564,2003.
64．Abreu-Velez AM, Beutner EH, Montoya F, Bollag WB, Hashimoto T: Analyses of autoantigens in a new form of endemic pemphigus foliaceus in Colombia. J Am Acad Dermatol 49(4):609-14,2003.
65．Abreu-Velez AM, Hashimoto T, Bollag WB, Tobon Arroyave S, Abreu-Velez CE, Londono ML, Montoya F, Beutner EH: A unique form of endemic pemphigus in northern Colombia. J Am Acad Dermatol. 49(4):599-608,2003.
66．Hisamatsu Y, Nishiyama T, Amano S, Matsui C, Ghohestani R, Hashimoto T: Usefulness of immunoblotting using purified laminin 5 in the diagnosis of anti-laminin 5 cicatricial pemphigoid. J Dermatol Sci. 33(2):113-119,2003.
67．Futei Y, Amagai M, Hashimoto T, Nishikawa T: Conformational epitope mapping and IgG subclass distribution of desmoglein 3 in paraneoplastic pemphigus. J Am Acad Dermatol 49(6):1023-1028,2003.
68．Shimanovich I, Hirako Y, Sitaru C, Hashimoto T, Brocker EB, Butt E, Zillikens D: The autoantigen of anti-p200 pemphigoid is an acidic noncollagenous N-linked glycoprotein of the cutaneous basement membrane. J Invest Dermatol. 121(6):1402-1408,2003.
69．Ohshima Y, Tamada Y, Matsumoto Y, Hashimoto T: Dermatitis herpetiformis Duhring with palmoplantar keratosis. Br J Dermatol. 149(6):1300-1302,2003.
70．Karlhofer FM, Hashimoto T, Slupetzky K, Kiss M, Liu Y, Amagai M, Pieczkowski F, Foedinger D, Kirnbauer R, Stingl G: 230-kDa and 190-kDa proteins in addition to desmoglein 1 as immunological targets in a subset of pemphigus foliaceus with a combined cell-surface and basement membrane zone immune staining pattern. Exp Dermatol. 12(5):646-654,2003.
71．Ishii N, Ishida-Yamamoto A, Hashimoto T: Immunolocalization of target autoantigens in IgA pemphigus. Clin Exp Dermatol. 29(1):62-66,2004.
72．Matsushima S, Horiguchi Y, Honda T, Fujii S, Okano T, Tanabe M, Wakayama T, Hashimoto T, Yancey KB: A case of anti-epiligrin cicatricial pemphigoid associated with lung carcinoma and severe laryngeal stenosis: review of Japanese cases and evaluation of risk for internal malignancy. J Dermatol 31(1):10-15,2004.
73．Fukumoto T, Umekawa T, Higuchi M, Hashimoto T, Shumann H, Bruckner-Tuderman L, Asada H, Miyagawa S: Childhood epidermolysis bullosa acquisita with autoantibodies against all 3 structural domains of type VII collagen. J Am Acad Dermatol 50(3):480-482,2004.
74．Lanschuetzer CM, Pohla-Gubo G, Schafleitner B, Hametner R, Hashimoto T, Salmhofer W, Bauer JW, Hintner H. Telepathology using immunofluorescence/immunoperoxidase microscopy. J Telemed Telecare 10:39-43,2004.
75．Izu K, Yamamoto O, Yasumoto S, Hashimoto T, Sata T, Tokura Y: Herpes zoster occurring as a solitary nodule on the index finger. Br J Dermatol 150(2):365-366,2004.
76．Hamada T, Ishii N, Kawano Y, Takahashi Y, Inoue M, Yasumoto S, Hashimoto T: The P25L mutation in the KRT5 gene in a Japanese family with epidermolysis bullosa simplex with mottled pigmentation.Br J Dermatol 150(3):609-611,2004.
77．Tsuda N, Kamura T, et.al.Vaccination with pre-designated or evidence-based peptides for patients with recurrent gynecologic cancers.J Immunotherapy 27:60-72,2004.
78．Nishio S, Kamura T, et.al.Weekly 1-h paclitaxel infusion in patients with recurrent endometrial cancer:a preliminary study.Int J Clin Oncol 8:45-48,2003.
79．Kojiro S, Kamura T, et.al.Primary leiomyoma of the ovary-a report of 2 resected cases-Kurume Med J50:169-172,2003.
80．Noguchi M, Kikuchi H, Ishibashi M, Noda S: Percentage of the positive area of bone metastasis is an independent predictor of the disease death in advanced prostate cancer. Br J Cancer 88: 195-201, 2003.
81．Noguchi M, Yahara J, Noda S: Serum levels of bone turnover markers parallel the results of bone scintigraphy in monitoring bone activity of prostate cancer. Urology 61: 993-998, 2003.
82．Yahara J, Noguchi M and Noda S.: Quantitative evaluation of bone metastases in prostatic cancer patients during systemic treatment. BJU Int 92:379-384, 2003
83．Noguchi M, Stamey T A and McNeal J E.: Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: lack of significance of secondary cancers. J Urol 170: 459-463, 2003.
84．Noguchi M, Yahara J, Motomori T and Noda S.: Transurethral
Vaporization For Giant Prostatic Hyperplasia: A Case Report.
85．Nakashima Y, Nakashima O, Tanaka M, Okuda K, Nakashima M, Kojiro M.Portal vein invasion and intrahepatic micrometastasis in small hepatocellular carcinama by gross type Hepatology Research 26 :142-147,2003.
86．Teshima H, Hayashida N, Yano H, Nishimi M, Tayama E, Fukunaga S, Akashi H,Kawara T, Aoyagi S.Obstruction of St Jude Medical Valves in the aortic position: Histology and immunohistochemistry of pannus. J. Thoracic. Cardiovasc. Surg 126(2) : 401-407, 2003.
87．Momosaki S, C.C.Hsia, Nakashima Y, Kojiro M, E. Tabor.Integration of hepatitis B virus containing mutations in the core promoter/X gene inpatients with hepatocellular carcinoma. Digestive and Liver Diseas 35:795-800 e, 2003.
88．Duo Liu, Tateno H, Ogino D, Suzuki M, Li Li, Wang Lu, Kojiro M, Fukayama M, Okabe H, Fukumoto M. Allelotypic Characteristics of Thorotrast-Induced Intrahepatic Cholangiocarcinoma : Comparison to Liver Cancers not Associated with Thorotrast RADIATION RESEARCH 161:235-243 , 2004.
89．Kojiro M. Focus on Dysplastic Nodules and Early Hepatocellular Carcinoma : An Eastern Point of View Liver Transplantation 10 (2Su1) : S3-S8, 2004.
90．Tsuji Y, Kumashiro R, Ishii K, Arinaga T, Sakamoto Y, Tanabe R, Ogata K, Koga Y, Ide T, Ono N, Tanaka E, Abe H, Sata M. Severe alcoholic hepatitis successfully treated by leukocytapheresis: A case report. Alcohol Clin Exp Res 27: 26s-31s,2003.
91．Seki R, Okamura T, Koga H, Yakushiji K, Hashiguchi M, Yoshimoto K, Ogata H, Imamura R, Nakashima Y, Kage M, Ueno T, Sata M. Prognostic significance of the F-box protein skp2 expression in diffuse large B-cell lymphoma. Am J Hematol 73: 230-235, 2003.
92．Sumie S, Yamashita F, Ando E, Tanaka M, Yano Y, Fukumori K, Sata M. Interventional radiology for advanced hepatocellular carcinoma: comparison of hepatic artery infusion chemotherapy and transcatheter arterial lipiodol chemoembolization. Am J Roentgenol 181: 1327-1334, 2003.
93．Nagaoka S, Yatsuhashi H, Hamada H, Yano K, Matsumoto T, Daikoku M, Arisawa K, Ishibashi H, Koga M, Sata M, Yano M. The des-γ-carboxy prothrombin index is a new prognostic indicator for hepatocellular carcinoma. Cancer 98: 2671-2677, 2003.
94．Kanauchi O, Mitsuyama K, Araki Y, Andoh A. Modification of intestinal flora in the treatment of inflammatory bowel disease. Curr Pharm Design 9: 333-346, 2003.
95．Nagao Y, Fukuizumi K, Kumashiro R, Tanaka K, Sata M. The prognosis for life in an HCV hyperendemic area. Gastroenterology 125: 628-629, 2003.
96．Ando E, Tanaka M, Yamashita F, Kuromatsu R, Takada A, Fukumori K, Yano Y, Sumie S, Okuda K, Kumashiro R, Sata M. Diagnostic clues for recurrent hepatocellular carcinoma: comparison of tumour markers and imaging studies. Eur J Gastroenterol Hepatol 15: 641-648, 2003.
97．Harada M, Kumemura H, Omary MB, Kawaguchi T, Maeyama M, Hanada S, Taniguchi E, Koga H, Suganuma T, Ueno T, Sata M. Proteasome inhibition induces inclusion bodies associated with intermediate filaments and fragmentation of the Golgi apparatus. Exp Cell Res 288: 60-69, 2003.
98．Shishido S, Koga H, Harada M, Kumemura H, Hanada S, Taniguchi E, Kumashiro R, Ohira H, Sato Y, Namba M, Ueno T, Sata M. Hydrogen peroxide overproduction in megamitochondria of troglitazone-treated human hepatocytes. Hepatology 37: 136-147, 2003.
99．Koga H, Harada M, Ohtsubo M, Shishido S, Kumemura H, Hanada S, Taniguchi E, Yamashita K, Kumashiro R, Ueno T, Sata M. Troglitazone induces p27Kip1-associated cell-cycle arrest through down-regulating Skp2 in human hepatoma cells. Hepatology 37: 1086-1096, 2003.
100．Harada M, Kawaguchi T, Taniguchi E, Kumemura H, Fujimatsu Y, Hanada S, Koga H, Harada R, Tanaka K, Okamura T, Kumashiro R, Aizawa H, Sata M. Unusual hyperbilirubinemia associated with bacterial pneumonia and acute myeloid leukemia. Hepatol Res 26: 114-118, 2003.
101．Nagamatsu Y, Kumashiro R, Itano S, Matsugaki S, Sata M. Investigation of associating factors in exacerbation of liver damage after chemotherapy in patients with HBV-related HCC. Hepatol Res 26: 293-301, 2003.
102．Kumashiro R, Kubota T, Koga Y, Tanaka M, Inada C, Kusaba N, Yoshida H, Hisamochi A, Ide T, Tomita Y, Masumoto N, Tanikawa K, Iga T, Sata M. Association of troglitazone-induced liver injury with mutation of the cytochrome P450 2C19 gene. Hepatol Res 26: 337-342, 2003.
103．Kuromatsu R, Tanaka M, Shimauchi Y, Harada R, Ando E, Itano S, Kumashiro R, Fukuda S, Okuda K, Sata M. Light and electron microscopic analyses of immediate and late tissue damage caused by radiofrequency ablation in porcine liver. Int J Mol Med 11: 199-204, 2003.
104．Harada M, Kumemura H, Sakisaka S,
Shishido S, Taniguchi E, Kawaguchi T, Hanada S, Koga H, Kumashiro R, Ueno T,
Suganuma T, Furuta K, Namba M, Sugiyama T, Sata M.
105．Ide T, Okamura T, Kumashiro R, Koga Y, Hino T, Hisamochi A, Ogata K, Tanaka K, Kuwahara R, Seki R, Sata M. A pilot study of eicosapentaenoic acid therapy for ribavirin-related anemia in patients with chronic hepaitis C. Int J Mol Med 11: 729-732, 2003.
106．Hino T, Kumashiro R, Ide T, Koga
Y, Ishii K, Tanaka E, Morita Y, Hisamochi A, Murashima S, Tanaka K, Ogata K,
Kuwahara R, Sata M, and The Autoimmune Hepatitis Study Group. Predictive factors
for remission and death in 73 patients with autoimmune hepatitis in
107．Kumashiro R, Kuwahara R, Ide T, Koga Y, Arinaga T, Hisamoto A, Ogata K, Tanaka K, Sata M. Subclones of drug-resistant hepatitis B virus mutants and the outcome of breakthrough hepatitis in patients treated with lamivudine. Intervirology 46: 350-4, 2003.
108．Kanauchi O, Serizawa I, Araki Y, Suzuki A, Andoh A, Fujiyama Y, Mitsuyama K, Takaki K, Toyonaga A, Sata M, Bamba T. Germinated barley foodstuff, a prebiotic product, ameliorates inflammation of colitis through modulation of the enteric environment. J Gastroenterol 38: 134-41, 2003.
109．Nagao Y, Hanada S, Shishido S, Ide T, Kumashiro R, Ueno T, Sata M. Incidence of Sjogren's syndrome in Japanese patients with hepatitis C virus infection. J Gastroenterol Hepatol 18: 258-266, 2003.
110．Miyamoto Y, Oho K, Kumamoto M, Toyonaga A, Sata M. Balloon-occluded retrograde transvenous obliteration improves liver function in patients with cirrhosis and portal hypertension. J Gastroenterol Hepatol 18: 934-942, 2003.
111．Ono N, Ijuin H, Suga H, Okabe Y,
Yakushiji K, Hashiguchi M, Kurohiji T, Koga N, Kumashiro R, Sata M. B-Flow
contrast US with levovist in hepatic tumors: Preliminary results.
112．Okabe Y, Ono N, Suga H, Ijuin H,
Kodama T, Narita K, Tsuruta O, Sata M, Toyonaga A. Effective extracorporeal
shock wave lithotripsy for pancreatic duct stone.
113．Kaji R, Sasaki N, Tateishi I,
Nagata E, Okabe Y, Yoshida T, Sata M, Ueno T. A case report of primary hepatic
squamous cell carcinoma that remarkably responded to low dose arterial injection
of anti-cancer drugs.
114．Inuzuka S, Tomiyasu N, Kumamoto M,
Egashira T, Kinoshita J, Shishido S, Sata M, Ueno T. A patient with
hyperlipidemia who had a gallbladder stone caused by administration of
fenofibrate.
115．Suzuki A, Kumashiro R, Shirachi M,
Kuroki M, Suzuki H, Tanikawa K Sata M. Markedly prolonged jaundice from
simultaneous infection with hepatitis E virus and leptospira.
116．Yoshimoto K, Ono N, Okamura T Sata M. Recent progress in the diagnosis and therapy for veno-occlusive disease of the liver. Leuk Lymphoma 44: 229-234, 2003.
117．Hanada S, Harada M, Koga H, Kawaguchi T, Taniguchi E, Kumashiro R, Ueno T, Ueno Y, Ishii M, Sakisaka S, Sata M. Tumor necrosis factor-α and interferon-γ directly impair epithelial barrier function in cultured mouse cholangiocytes. Liver Int 23: 3-11, 2003.
118．Yano Y, Yamashita F, Sumie S, Kuwaki K, Yamamoto H, Toyoda N, Ando E, Tanaka M, Sata M. Clinical significance of antibody against hepatitis B virus core antigen in patients with hepatitis C virus-related hepatocellular carcinoma. Liver Int 23: 227-231, 2003.
119．Hashimoto O, Ueno T, Kimura R, Ohtsubo M, Nakamura T, Koga H, Torimura T, Uchida S, Yamashita K, Sata M. Inhibition of proteasome-dependent degradation of Wee1 in G2-arrested Hep3B cells by TGFβ1. Mol Carcinog 36: 171-182, 2003.
120．Tsuda H, Sata M, Kumabe T, Uchida M, Hara H. The preventive effect of antineoplaston AS2-1 on HCC recurrence. Oncol Rep 10: 391-397, 2003.
121．Ogata Y, Tsuda H, Matono K, Kumabe T, Saitsu H, Hara H, Akagi Y, Araki Y, Sata M, Shirouzu K. Long-term survival following treatment with antineoplastones for colon cancer with unresectable multiple liver metastases: Report of a case. Surg Today 33: 448-453, 2003.
122．Ide T, Kumashiro R, Koga Y, Tanaka E, Hino T, Hisamochi A, Murashima S, Ogata K, Tanaka K, Kuwahara R, Sata M. A real-time quantitative polymerase chain reaction method for hepatitis B virus in patients with chronic hepatitis B treated with lamivudine. Am J Gastroenterol 98: 2048-2051, 2003.
123．Hisaeda K, Inokuchi A, Nakamura T, Kohno K, Iwamoto Y, Kuwano M and Uchiumi T. IL-1β represses multidrug resistance protein2 gene expression through inactivation of IRF3 in human hepatic cells. Hepatology. in press,2004.
124．Shibahara K, Uchiumi T, Fukuda T, Kura S, Tominaga Y, Maehara Y, Kohno K, Nakabeppu Y, Tsuzuki T and Kuwano M. Targeted disruption of one allele of the Y-box binding-1 (YB-1) gene in mouse embryonic stem cell and increased sensitivity to cisplatin and mitomycin C. Cancer Science. in press,2004.
125．Ono M, Hirata A, Kometani T, Miyagawa M, Ueda S, Kinoshita H, Fujii T and Kuwano M. Sensitivity to gefitinib (Iressa: ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the EGF receptor / ERK1/2 and EGF receptor /AKT pathway for proliferation. Molec. Cancer Therapeutics. in press,2004.
126．Kuwano T, Nakao S, Yamamoto H, Tsuneyoshi M, Yamamoto T, Kuwano M and Ono M. Cyclooxygenase 2 is a key enzyme for inflammatory cytokinase-induced angiogenesis. FASEB J, 18: 300-310, 2004.
127．Fukuda T, Ashizuka M, Nakamura T, Shibahara K, Maeda K, Izumi H, Kohno K, Kuwano M and Uchiumi T. Characterization of 5'-untranslated region of YB-1 mRNA and autoregulation of translation by YB-1 protein. Nucleic Acids Res, 32: 611-622, 2004.
128．Taniguchi S, Mochida Y, Uchiumi T, Tahira T, Hayashi K, Takagi K, Shimada M, Maehara Y, Kuwano H, Kono S, Nakao H, Kuwano M and Wada M. Genetic polymorphism at the 5' regulatory region of multidrug resistance 1 (MDR1) and its association with interindividual variation of expression level in the colon. Molec. Cancer Therapeutics, 2: 1351-1359, 2003.
129．Wakisaka Y, Furuta A, Masuda K, Morikawa W, Kuwano M and Iwaki T. Cellular distribution of NDRG1 protein in the rat kidney and brain during normal postnatal development. J. Histochem. Cytochem, 51: 1515-1525, 2003.
130．Mochida Y, Taguchi K I, Taniguchi S, Tsuneyoshi M, Kuwano H, Tsuzuki T, Kuwano M and Wada M. The role of P-glycoprotein in intestinal tumorigenesis: disruption of mdrla suppresses polyp formation in ApcMin/+ mice. Carcinogenesis, 24: 1219-1224, 2003.
131．Kohno K, Izumi H, Uchiumi T, Ashizuka M and Kuwano M. The pleiotropic functions of the Y-box-binding protein, YB-1. Bio Essays, 25: 691-698, 2003.
132．Saji H, Toi M, Saji S, Koike M, Kohno K and Kuwano M. Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human breast carcinoma. Cancer Lett, 190: 191-197, 2003.
133．Konno T, Ebihara T, Hisaeda K, Uchiumi T, Nakamura T, Shirakusa T, Kuwano M and Wada M. Identification of domains participating in the substrate specificity and subcellular localization of the multidrug resistance proteins MRP1 and MRP2. J. Biol. Chem, 278: 22908-22917, 2003.
134．Oda Y, Ohishi Y, Saito T, Hinoshita E, Uchiumi T, Kinukawa N, Iwamoto Y, Kohno K, Kuwano M and Tsuneyoshi M. Nuclear expression of Y-box-binding protein-1 correlates with P-glycoprotein and topoisomerase2 alpha expression, and with poor prognosis in synovial sarcoma. J. Pathol, 199: 251-258, 2003.
135．Masuda K, Ono M, Okamoto M, Morikawa W, Otsubo M, Migita T, Tsuneyoshi M, Okuda H, Shuin T, Naito S and Kuwano M. Downregulation of CAP43 gene by von Hippel-Lindau tumor suppressor protein in human renal cancer cells. Int. J. Cancer, 105: 803-810, 2003.
136．Nakao S, Kuwano T, Ishibashi T, Kuwano M and Ono M. Synergistic effect of TNF-α in soluble VCAM-1-induced angiogenesis through α4 integrins. J. Immunol, 170: 5704-5711, 2003.
137．Kuwano M, Uchiumi T, Hayakawa H, Ono M, Wada M, Izumi H and Kohno K. The basic and clinical implications of ABC transporters, Y-box-binding protein-1 (YB-1) and angiogenesis-related factors in human malignancies. Cancer Science, 94: 9-14, 2003.
138．Umezu Y, Shiba N, Tajima F, Mizushima T, Okawa H, Ogata H, Nagata K, Basford JR：Muscle endurance and power spectrum of the triceps brachii in wheelchair marathon racers with paraplegia.Spinal Cord, 41:511-515, 2003.;
139．Sato K, Nagata K, Sugita Y.：Spinal extradural meningeal cyst:correct radiological and histopathological diagnosis．Neurosurgical Focus, 13 (4):Clinical Pearl 1, 1-4, 2002.
140．Soejima T, Murakami H, Tanaka N, Nagata K.: Anteromedial meniscofemoral ligament. Arthroscopy, 19:90-95, 2003.
141．Soejima T, Murakami H, Tanaka N, Sato K, Nagata K. Sugita Y.: Fasciitis-Like proliferation in the knee joint. Arthroscopy, 19:E33:1-4, 2003.
142．Yanagi T, Shiba N, Maeda T, Iwasa K, Umezu Y, Tagawa Y, Matsuo S, Yamamoto T, Nagata K, Jeffrey R. Basford: Agonist contractions against electrically stimulated antagonists．Arch Phys Med Rehabil, 84:843-848, 2003.
143．Araki Y, Isomoto H, Shirouzu K：Video-Assisted Gasless Transanal Endoscopic Microsurgery：A Review of 217 Cases of Rectal Tumors over the Past 10 Years. Dig Surg, 20:48-52, 2003.
144．Terazaki Y, Yano S, Yuge K, Nagano S, Fukunaga M, Z.Sheng Guo, Komiya S, Shirouzu K and Kosai K :An Optimal Therapeutic Expression Level Is Crucial for Suicide Gene Therapy for Hepatic Metastatic Cancer in Mice. HEPATOLOGY, 37:155-163, 2003.
145．Yahara T, Koga T, Yoshida S, Nakagawa S, Deguchi H and Shirouzu K: Relationship Between Microvessel Density and Thermographic Hot Areas in Breast Cancer.surg Today, 33:243-248, 2003.
146．Aoyagi K, Koufuji K, Yano S, Miyagi M, Koga A, Takeda J And Shirouzu K :A Case of Small Mucosal Gastric Carcinoma With Lymph Node Metastasis：A Case Report. Kurume Medical Journal, 50:49-51, 2003.
147．Aoyagi K, Koufuji K, Yano S, Murakami N, Miyagi M, Koga A, Takeda J and Shirouzu K :The Expression of p53, p21 and TGF β1 in Gastric Carcinoma. Kurume Medical Journal, 50:1-7, 2003.
148．Aoyagi K, Koufuji K, Yano S, Miyagi M, Koga A, Takeda J and Shirouzu K :Two Cases of Early Gastric Carcinoma with Synchronous Liver Metastasis. Kurume Medical Journal, 50:53-56, 2003.
149．Aoyagi K, Koufuji K, Yano S, Miyagi M, Koga A, Takeda J and Shirouzu K : α-Fetoprotein-Producing Early Gastric Cancer : Report of Two Cases. Kurume Medical Journal , 50:63-66, 2003.
150．Tokuhara K, Oagata Y, Nakagawa M, Shirouzu K : Ets-1 Expression in Vascular Endothelial Cells as an Angiogenic and Prognostic Factor in Colorectal Carcinoma. Int Surg, 88:25-33, 2003.
151．Sasatomi T, Yamana H, Shichijo S, Tanaka S, Okamura T, Ogata Y, Itoh K, Shirouzu K : Expression of the SART1 Tumor-Rejection Antigens in Colorectal Cancers. Dis Colon Rectum, 43:1754-1758, 2003.
152．Shirouzu K, Ogata Y, Araki Y, Kishimoto Y, Sato Y : A new Ultimate anus-preserving operation for extremely low rectal cancer and for anal canal cancer. Techniques in Coloproctology, 7:203-206, 2003.
153．Araki Y, Noake T, Hata H, Momosaki K, Shirouzu K : Perianal Paget's Disease Treated With a Wide Excision and Gluteal Fold Flap Reconstruction Guided by Photodynamic Diagnosis. Dis Colon Rectum, 46:1563-1566, 2003.
154．Araki Y, Ishibashi N, Sasatomi T, Kanazawa M, Ogata Y and Shirouzu K : Effectiveness of the portable ultrasound bladder scanner in the measurement of residual urine volume after total mesorectal extirpation. Min lnvas Ther ＆Allied Technol, 12:245-248, 2003.
155．Tamura K, Takamori S, Hayashi A, Miwa K, Fukunaga M, Maeshiro K, Nakamura H, Tamae T, Isomoto H, and Shirouzu K : Resection of Synchronous Lung and Vater’s Papilla Cancer. Kurume Medical Journal, 50:143-146, 2003.
156．Nozoe Y, Ogata Y, Araki Y, Sasatomi T, Fukumori H and Shirouzu K : Up-regulation in Dihydropyrimidine Dehydrogenase Activity by Raltitrexed Causes Antagonism in Combination with 5-Fluorouracil.ANTICANCER RESEARCH, 23:4663-4670, 2003.
157．Ishibashi N, Yoshida S, Kaibara A, Shirouzu Y, Kamei H, Tajiri T, Muraoka T, Tanaka K, Ozaki K, Iwakuma N, Momosaki K, Oka Y, Toh U, Kido K and Shirouzu K :Recent advance for crucial role in intra-cerebral TNFα expression during surgical stress. Recent Res.Devel.Physiol, 1:785-792, 2003.
158．Tamura K, Takamori S, Hayashi A, Miwa K, Fukunaga M, Maeshiro K, Nakamura H, Tamae T, Isomoto H and Shirouzu K : Resection of Synchronous Lung and Vater’s Papilla Cancer. Kurume Medical Journal, 50:143-146, 2003.
159．藤田博正、末吉 晋、田中寿明、笹原弘子、的野 吾、山名秀明、白水和雄、鈴木 弦、早渕尚文：食道癌のChemoradiotherapy. 癌と化学療法30(7):937-943, 2003.
160．山名秀明：食道癌の集学的治療．外科 65(9): 1076-1080, 2003.
161．的野 吾、藤田博正、末吉 晋、田中寿明、笹原弘子、森 直樹、李 美慧、山名秀明、白水和雄、立石秀夫、豊永 純、中島 格：食道癌と紛らわしい食道疾患．臨床外科 58(9): 1199-1204, 2003.
162．山名秀明、伊東恭悟：２．癌ワクチン．臨床腫瘍学3版、日本臨床腫瘍学会編、癌と化学療法社、pp326-336, 東京､2003(11月).
163．唐 宇飛、山名秀明、木戸浩一郎、峯 孝志、藤井輝彦、堀内彦之、笹冨輝男､石橋生哉、藤田博正、白水和雄：癌局所療法としての細胞免疫療法による癌患者免疫状態への影響とその臨床効果．癌と化学療法30(11): 1566-1570, 2003.
164．峯 孝志、伊東恭悟、山名秀明：腫瘍ワクチン療法：テーラーメイド型ペプチドワクチン創薬への展開。Surgery Frontier, 10(4):380-384, 2003.
165．田中寿明、末吉 晋、笹原弘子、的野 吾、山名秀明、白水和雄、藤田博正：再発食道癌に対するDocetaxel, 5-FU, CDDPを用いた化学療法 －Pilot Studyとして－．癌と化学療法30(12): 1955-1958, 2003.
166．中原慶太、立石秀夫、鶴田 修、豊永 純、佐田通夫、武田仁良、有馬信之：画像所見と切除標本・組織所見を対比した表層拡大型早期胃癌の1例．胃と腸38: 664-667, 2003.
167．上野隆登、吉田一郎、林 明宏、高城喜典、渡邊誠之、黒木岳人、吉村浩一、牛島公生、末安禎子、松尾和彦、鳥村拓司、安陪等思、宮崎 洋、香野修介、赤木禎治、中島 裕、佐田通夫：基本的臨床技能習得のためのスキルスラボの導入とその有用性．医学教育 34: 81-87, 2003.
168．神代龍吉、日野照子、古賀郁利子、久持顕子、有松秀敏、桑原礼一郎、久米村寛大、井出達也、田中英介、佐田通夫：やせ薬による薬物性急性肝炎．肝臓 44: 113-116, 2003.
169．古賀裕之、田口 順、石井邦英、井上欣哉、佐藤公昭、實藤俊昭、梶原雅彦、安倍弘彦、神代龍吉、佐田通夫：中国製ダイエット食品による劇症肝炎・亜急性型の 1 救命例．肝臓 44:117-122, 2003.
170．坂井慈実、池尻直幹、古賀郁利子、神代龍吉、安倍弘彦、佐田通夫、谷川久一：アルコール性肝硬変に伴う肝性脳症に対するベンゾジアゼピン拮抗薬の持続投与の効果．肝臓 44: 283-289, 2003.
171．板野 哲、原田 大、永松洋明、松垣 諭、山崎三樹、田尻能祥、黒木淳一、池尻直幹、神代龍吉、佐田通夫：アルコール性肝硬変症における Tc-99 m-GSA 肝シンチグラフィ．肝臓 44: 290-295, 2003.
172．窪山信一、石井邦英、古賀裕之、井上欣哉、家村昭日朗、實藤俊昭、梶原雅彦、安倍弘彦、小野尚文、豊永 純、佐田通夫：MR Lymphography による肝硬変疾患者胸管の観察 - 腹水との関連において -．肝臓44: 333-337, 2003.
173．神代龍吉、古賀郁利子、久持顕子、桑原礼一郎、安倍弘彦、石井邦英、釈迦堂敏、酒井浩徳、小野典之、白地美紀、福嶋博文、白地 哲、山下文彦、矢野洋一、宮島一郎、佐田通夫：消化器病患者における健康食品の摂取状況. 肝臓 44: 435-442, 2003.
174．田口 順、石井邦英、梶原雅彦、井上欣哉、古賀裕之、實藤俊昭、安倍弘彦、中島 収、神代正道、佐田通夫：NASH (非アルコール性脂肪性肝炎) による肝硬変に多中心性発生したと考えられる肝細胞癌の1剖検例. 肝臓 44: 559-564, 2003.
175．居石哲治、神代龍吉、伊藤 実、豊永 純、佐田通夫：脳血管障害後遺症に伴う長期的臥床患者における消化器官関連機能変化の検討. 消化と吸収 26: 60-63, 2003.
176．草場信秀、吉田 博、中野 均、横田泰司、河野 亨、川内敦文、佐田通夫：福岡県八女・筑後医療圏における C 型肝炎ウイルス対策. 全自病協雑誌 42: 900-901,2003.
177．辻雄一郎、鶴田 修、河野弘志、唐原 健、吉森建一、佐田通夫、豊永 純、有馬信之：Is型ポリープが3年間で Is + IIc 型 sm 癌に進展した1例. 早期大腸癌 7: 59-61, 2003.
178．鶴田 修、河野弘志、辻雄一郎、唐原 健、吉森建一、豊永 純、佐田通夫：結節集簇様病変 (LST granular type) から進展したと考えられる大腸進行癌の 1 例. 早期大腸癌 7: 156-157, 2003.
179．久持顕子、神代龍吉、古賀郁利子、田中英介、井出達也、日野照子、村島史朗、緒方 啓、桑原礼一郎、古賀浩徳、宍戸昌一郎、上野隆登、佐田通夫、江口尚久. ピオグリタゾンによる薬物性肝障害の 1 例. 日本消化器病学会雑誌 100: 333-336, 2003.
180．福森一太、安東栄治、山下文彦、田中正俊、住江修治、矢野洋一、釈迦堂 敏、佐田通夫：Cisplatin と 5-fluorouracil による動注化学療法不変例に対し epirubicin の chemolipiodolization で完全寛解が得られた高度進行肝細胞癌の 1 例. 日本消化器病学会雑誌 100: 448-453, 2003.
181．福森一太、釈迦堂 敏、巻幡徹二、武元良裕、福泉公仁隆、宮原稔彦、安森弘太郎、村中 光、渡辺次郎、才津秀樹、酒井浩徳、佐田通夫：肝細胞癌に対する経皮的ラジオ波焼灼療法術後に高カリウム血症を来した慢性腎不全患者の 1 例. 日本消化器病学会雑誌 100: 702-706, 2003.
182．武元良祐、釈迦堂 敏、山下尚毅、西 秀博、福森一太、福泉公仁隆、宮原稔彦、酒井浩徳、安森弘太郎、村中 光、高見裕子、才津秀樹、渡辺次郎、佐田通夫：テガフール・ギメラシル・オテラシルカリウム配合カプセル剤 (TS-1) が奏効した肝細胞癌の 1 例. 日本消化器病学会雑誌 100: 1123-1128, 2003.
183．中尾新太郎、石橋達朗、桑野信彦、小野眞弓：VCAM-1/α4インテグリンを介する血管新生のシグナル伝達機構．臨床免疫41:200-204, 2004.
184．桑野信彦、和田守正、和泉弘人、河野公俊：多剤耐性トランスポーター：抗がん剤のMDR 臨床薬理35-32 『特集／トランスポーター』 三原医学社 印刷中
185．藤井輝彦、山名秀明、桑野信彦：胃がんにおける血管新生因子阻害剤．臨牀消化器内科 日本メディカルセンター 印刷中
186．桑野信彦、藤井輝彦、小野眞弓、河野公俊：序文：分子標的治療の現状と将来への展望．日本臨牀 日本臨牀社 印刷中
187．和田守正、桑野信彦：膀胱癌のDNAメチル化異常と臨床応用．現代医療35：155-166, 2003.
188．永田見生，佐藤公昭，安藤則行，高宮啓彰，神保幸太郎：術後Ｃ５随節麻痺の病態と対策．整形・災害外科46：497-502, 2003.
189．永田見生，佐藤公昭，安藤則行，高宮啓彰，神保幸太郎：骨粗鬆症性脊椎骨折に伴う下肢神経障害に対する後方アプローチによる手術療法.日本整形外科学会雑誌77：S624, 2003.
190．永田見生：脊椎軟骨肉腫．脊椎脊髄ジャーナル16：1165-1170, 2003.
191．樋口富士男：特集・人工股関節における摩耗と予防・metal on metalセメント使用の人工股関節の中期成績．関節外科22：73-79, 2003.
192．志波直人，中島義博，前田貴司，梅津祐一，岩崎敏展，柳東次郎，荻野美佐，松尾重明，田川善彦，中村英智，永田見生：股関節機能障害者の歩行解析．臨床バイオメカニクス23：277-281, 2003.
193．白濱正博，坂井健介，田中邦彦，永田見生：股関節後方脱臼骨折における寛骨臼後壁骨折の検討．骨折25：404-407, 2003.
194．白濱正博，坂井健介，永田見生：髄内釘併用骨延長術による治療．整形外科54：644-648, 2003.
195．佐藤公昭，永田見生：腰痛の理学療法とリハビリテーション．臨床と研究80：439-444, 2003.
196．佐藤公昭，永田見生：特集：実践腰部椎間板ヘルニア診療テクニックマニュアルA．病態 画像診断からみた病態．MB Orthop 16：3-8, 2003.
197．佐藤公昭，永田見生，安藤則行，高宮啓彰，神保幸太郎，吉光一浩：腰椎椎間板ヘルニアに対するLove変法のクリティカルパス．整形外科54：992-998, 2003.
198．佐藤公昭，永田見生，安藤則行，高宮啓彰，神保幸太郎：硬膜外髄膜嚢腫の手術例の検討．日本脊椎脊髄病学会雑誌14：387, 2003.
199．佐藤公昭，安藤則行，副島 崇，村上秀孝，金澤知之進，永田見生：頚椎後縦靭帯骨化症に対する棘突起縦割式椎弓形成術の手術成績．整形災害と災害外科52：341-345, 2003.
200．佐藤公昭，安藤則行，仲摩憲次郎，永田見生：40歳以下の頚髄症の手術例の検討．整形災害と災害外科52：60-63, 2003.
201．副島 崇、村上秀孝、田中信博、阿部隆伸、永田見生：前十字靭帯再建術における術後短期の再鏡視所見と中期成績との関連．膝27：229-232, 2003.
202．久保 学，大川孝浩，熊谷 優，樋口富士男，永田見生，井上明生：Kerboull十字プレートを用いた臼蓋再建術の検討．日本整形外科学会雑誌77：S458, 2003.
203．久保 学，大川孝浩，熊谷 優，永田見生：Ortho Scopeを用いた人工股関節再置換術．Hip Joint 29：587-591, 2003.
204．熊谷 優，大川孝浩，永田見生，水野泰之，J. J. Elias,
205．熊谷 優，大川孝浩，久保 学，永田見生：Mobile bearing TKR fixed bearing TKR の膝関節動態パターン．Journal of Musculoskeletal System 16：181-185, 2003.
206．熊谷 優，大川孝浩，久保 学，永田見生，樋口冨士男，井上明生：特発性大腿骨頭壊死症に対する Bipolar 型人工骨頭置換術の中・長期成績．Hip Joint 29：239-242, 2003.
207．熊谷 優，大川孝浩，久保 学，金澤武利，永田見生：大腿骨側 cement 使用の有無における THR 術後の肺血流シンチの比較検討．日本整形外科学会 77：S222, 2003.
208．朴 珍守，永田見生：リマプロスト投与が著効した腰部脊柱管狭窄症の２例．Pharma Medica 21：138-140, 2003.
209．山田 圭，吉田健治，山下 寿，後藤琢也，佐藤公昭，永田見生：治療に難渋した脊髄硬膜外血腫の1例．脊椎・脊髄神経手術手技 5：96-99, 2003.
210．金澤武利，大川孝浩，久保 学，熊谷 優，久米慎一郎，別府俊介，三宮貴彦，樋口富士男，永田見生，井上明生：重度臼蓋形成不全を有する前初期股関節症に対するChiari骨盤骨切り術の長期成績．整形外科と災害外科 52：10-17, 2003.
211．孝冨士喜久生，武田仁良，青柳慶史朗，矢野正二郎，村上直孝，宮城委史，古閑敦彦，白水和雄：十二指腸浸潤胃癌症例の検討.臨床と研究 121-124, 2003.
212．野副安宏，大野高義，松永和子，竹尾正彰，荒木靖三，白水和雄：内視鏡的胃瘻増設術困難な例に対するPTEG(percutaneous trans esophageal gastro-tubing)施行の経験.臨床と研究 80 :190-192, 2003.
213．的野敬子，緒方 裕，荒木靖三，笹富輝男，石橋生哉，金澤昌満，岸本幸也，津田英照，才津英樹，白水和雄：生化学的抗腫瘍剤アンチネオプラストンが奏功した大腸癌切除不能多発肝転移の1例.臨床と研究 80 : 373-376, 2003.
214．藤田博正，末吉 晋，田中寿明，白水和雄：Q22 頸部での食道・胃吻合のコツは？.臨床外科 58 : 350-352, 2003.
215．孝冨士喜久生，武田仁良，青柳慶史朗，矢野正二郎，村上直孝，古閑敦彦，宮城委史，白水和雄：高度腹膜播種陽性胃癌症例の検討. 臨床と研究 80 : 467-470, 2003.
216．光岡正浩, 三輪啓介, 高森信三, 林 明宏, 納富昌徳, 白水和雄：頸部気管内Dumonステント留置時の工夫.気管支学 25 : 80-84, 2003.
217．末吉 晋, 藤田博正, 田中寿明, 笹原弘子, 白水和雄:久留米大学の手術方針と手技.手術 57:449-455, 2003.
218．青柳慶史朗, 孝冨士喜久生, 矢野正二郎, 宮城委史, 古閑敦彦, 武田仁良, 白水和雄：胃癌単一リンパ節転移症例よりみたセンチネルリンパ節の検討.月刊臨床と研究 別冊80:71（889）-75（893）, 2003.
219．白水和雄,緒方 裕,荒木靖三：下部直腸癌に対する究極の肛門温存術 -深・浅外肛門括約筋合併切除を伴う経肛門的結腸肛門吻合術-.手術 57:729-736, 2003.
220．孝冨士喜久生,武田仁良,青柳慶史朗,矢野正二郎,宮城委史,古閑敦彦,白水和雄：漿膜浸潤胃癌再発形式に関する臨床病理学的検討.月刊 臨床と研究 別冊80:104（1088）-107（1091）, 2003.
221．荒木靖三,小篠洋之,佐藤裕一郎,鳥越昇二郎,的野敬子,石橋生哉,金澤昌満,笹富輝男,緒方 裕,白水和雄：潰瘍性大腸炎に対するLiga Sure Atlasを用いた腹腔鏡ハンドアシスト法による大腸全摘術.月刊 臨床と研究 別冊80:200（1184）-202（1186）, 2003.
222．平川道子,荒木靖三,白水和雄：ストーマの管理.消化器外科 909-915, 2003.
223．田中寿明，末吉 晋，笹原弘子，山名秀明，白水和雄，藤田博正：食道癌に対する化学療法レジメン －術前・術後補助・再発例-. 臨床外科 58:1035-1040, 2003.
224．緒方 裕，白水和雄：熱凝固治療（マイクロ波凝固療法およびラジオ波薬灼療法）. 再発大腸癌治療ガイドブック 107-112, 2003.
225．白水和雄：大腸癌治癒切除後の再発. 再発大腸癌治療ガイドブック 7-16, 2003.
226．緒方 裕，荒木靖三，白水和雄：Ⅵ．腫瘍 2.肛門管癌の診断と治療. 外科 65 : 819-824, 2003.
227．的野 吾，末吉 晋，藤田博正，白水和雄：食道癌手術における自己血輸血の意義～同種血輸血回避を目指して～. 自己血輸血 16:41-46, 2003.
228．緒方 裕，的野敬子，白水和雄:大腸癌の診断と治療～最新の研究動向～.日本臨床 61:505-509, 2003.
229．金澤昌満，白水和雄：11.直腸癌. 消化器外科スタッフマニュアル 401-405, 2003.
230．笹富輝男，白水和雄：消化器癌に対する癌ワクチン療法. 消化器癌のサーベイランス 315-319, 2003.
231．荒木靖三，白水和雄：直腸腫瘍に対する経肛門的内視鏡下手術. 外科治療 89:380-385, 2003.
232．藤田博正，末吉 晋，田中寿明，笹原弘子，的野 吾，白水和雄：T4食道癌治療における外科的切除の意義. 臨床消化器内科 18:1515-1521, 2003.
233．青柳慶史朗，孝冨士喜久生，矢野正二郎，宮城委史，古閑敦彦，武田仁良,白水和雄：未分化型隆起性胃癌の臨床病理学的検討. 臨床と研究 80:2046-2051, 2003.
234．真栄城兼誉，高森信三，寺崎泰宏，三輪啓介，福永真理，中村寿，林 明宏，坂本照夫，白水和雄：外傷性右隔膜破裂の4例. 日本呼吸器外科学会雑誌 17:32（740）-38（746）, 2003.
235．荒木靖三，白水和雄：直腸腫瘍に対する経肛門的内視鏡下手術. 外科治療 89:380-385, 2003.
236．福光賞真，緒方 裕，荒木靖三，白水和雄：直腸癌のリンパ節転移～リンパ節転移危険因子と非危険因子～.消化器科 37:115-120, 2003.
237．大塚隆彦，荒木靖三，金澤昌満，緒方 裕，笹富輝男，石橋生哉，鳥越昇二郎,岡 洋右，福光賞真，佐藤裕一郎，的野敬子，白水和雄：孤立性内腸骨動脈瘤を併発した直腸癌の1例.臨床と研究 80:103（2059）-105（2061）, 2003.
238．青柳慶史朗，孝冨士喜久生，矢野正二郎，宮城委史，古閑敦彦，武田仁良，白水和雄：StageⅡ漿膜浸潤陽性胃癌の検討.臨床と研究 80:84（1498）-89（1503）, 2003.
239．緒方 裕，白水和雄：プロテアソーム阻害剤（抗癌剤との相乗効果や耐性の克服）.Surgery Frontier 10:53-55, 2003.
240．赤木由人,白水和雄,緒方 裕：肛門部の悪性腫瘍とその治療. 外科治療89:667-73, 2003.
241．藤田博正,末吉 晋,田中寿明,笹原弘子,的野 吾,白水和雄：食道癌手術における胸部大動脈周囲のリンパ節郭清術. 手術 58:7-12, 2004.
242．笹富輝男,白水和雄：消化器癌のサーベイランス. ４．消化器癌に対する癌ワクチン療法.（株）新興医学出版社 315-319, 2003.
243．孝冨士喜久生，武田仁良，青柳慶史朗，矢野正二郎，宮城委史，古閑敦彦 今泉拓也，白水和雄：食道浸潤早期胃癌症例の検討. 癌の臨床 1627（11）-1629（13）, 2003.
244．孝冨士喜久生,武田仁良,青柳慶史朗,矢野正二郎,宮城委史,古閑敦彦,白水和雄：十二指腸浸潤早期胃癌症例の検討. 癌の臨床 211-213, 2003.
245．孝冨士喜久生,武田仁良,青柳慶史朗,矢野正二郎,宮城委史,古閑敦彦,今泉拓也,白水和雄：幽門輪より3㎝未満にみられた早期胃癌症例の検討. 臨床と研究 2234-2236, 2003.
246．助廣亜希、津田尚武、望月一生、田村真由美、雲井加代子、伊東恭悟：癌ペプチドワクチン臨床試験を受ける再発婦人科がん患者の看護. 日本がん看護学会誌 17:43-54, 2003.
247．田村真由美、伊東恭悟：臨床試験リサーチナースの役割-臨床研究の立場から-. 日本看護学会誌17:47-51, 2003.
248．古田雅俊、由谷茂、峯孝志、伊東恭悟：医師主導型臨床試験における電子カルテ導入に向けての検討. 医療とIT. 2004/2 .
|